2011
DOI: 10.1007/s00404-011-1855-4
|View full text |Cite
|
Sign up to set email alerts
|

Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature

Abstract: The safety of chemotherapy during pregnancy is debatable. We present a case of advanced ovarian cancer, diagnosed at week 28 of gestational age, treated with 2 cycles of paclitaxel/cisplatin (TC) chemotherapy during pregnancy, with no serious toxicity. At week 34, the patient underwent a caesarean section and delivered a healthy girl. Four additional cycles of TC were administered. Three months after completing chemotherapy, the patient developed abdominal progression and subsequently a huge metastatic cystic … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
21
0

Year Published

2011
2011
2018
2018

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 28 publications
(21 citation statements)
references
References 20 publications
0
21
0
Order By: Relevance
“…Each year in the United States, approximately 21,200 women are diagnosed with OvCa (2200<45 years of age), and 14,300 die from the disease (470<45 years of age) (Pollack et al, 2009). The standard therapy for advanced epithelial ovarian cancer (EOC) consists of cytoreductive surgery followed by chemotherapy, preferably including paclitaxel combined with cisplatin or carboplatin (Serkies et al, 2011). It is because of the rational use of operation and chemotherapy, that the estimated 5-year relative survival for women diagnosed with OvCa in 2006 was 44.0%, an increase from 36.1% for those diagnosed between 1975 to 1977 (Eheman et al, 2006).But drug toxicity and high price greatly limit the use of these drugs.…”
Section: Introductionmentioning
confidence: 99%
“…Each year in the United States, approximately 21,200 women are diagnosed with OvCa (2200<45 years of age), and 14,300 die from the disease (470<45 years of age) (Pollack et al, 2009). The standard therapy for advanced epithelial ovarian cancer (EOC) consists of cytoreductive surgery followed by chemotherapy, preferably including paclitaxel combined with cisplatin or carboplatin (Serkies et al, 2011). It is because of the rational use of operation and chemotherapy, that the estimated 5-year relative survival for women diagnosed with OvCa in 2006 was 44.0%, an increase from 36.1% for those diagnosed between 1975 to 1977 (Eheman et al, 2006).But drug toxicity and high price greatly limit the use of these drugs.…”
Section: Introductionmentioning
confidence: 99%
“…Checking all the references of relevant reviews and eligible articles, 1 more study was included. Overall, 9 studies were eligible for the systematic review [6,7,8,9,10,11,12,13,14] (table 1). The aforementioned stages are illustrated in detail in figure 1.…”
Section: Resultsmentioning
confidence: 99%
“…In relation to paclitaxel, 8 articles (11 pregnancies, 12 newborns) were retrieved [6,7,8,9,10,11,12,14], while regarding docetaxel, 1 article (1 pregnancy, 1 newborn) was identified [13]. The mean age of ovarian cancer patients at diagnosis was 33 years (SD 5.1; median 33; range 24–42) [6,7,8,9,10,11,12,13,14].…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations